Management of patients with intermediate stage hepatocellular carcinoma

doi:10.1177/1758835920970840

科研成果详情

题名	Management of patients with intermediate stage hepatocellular carcinoma
作者	Prince, David 1; Liu, Ken 1; Xu, Weiqi 2; Chen, Minjiang3; Sun, Jin-Yu 4; Lu, Xiao-Jie 4; Ji, Jiansong 5
发表日期	2020-11
发表期刊	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 影响因子和分区
语种	英语
原始文献类型	Review
关键词	BCLC staging hepatocellular carcinoma intermediate stage locoregional therapy transarterial chemoembolization
其他关键词	TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION ; DOXORUBICIN-ELUTING BEADS ; CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION ; CLINICAL-PRACTICE GUIDELINES ; RANDOMIZED CONTROLLED-TRIAL ; LIVER-TRANSPLANTATION ; SURVIVAL RATES ; PHASE-II ; RADIOFREQUENCY ABLATION ; YTTRIUM 90
摘要	Hepatocellular carcinoma (HCC) causes a significant health burden globally and its impact is expected to increase in the coming years. Intermediate stage HCC, as defined by the Barcelona Clinic Liver Cancer (BCLC) system stage B, represents up to 30% of patients at diagnosis and encompasses a broad spectrum of tumor burden. Several attempts have been made to further subclassify this heterogenous group. The current standard of care recommended by BCLC for intermediate stage HCC patients is transarterial chemoembolization (TACE), with modest outcomes reported. While refinements have been made to TACE technique and patient selection, it remains non-curative. In the real-world setting, only 60% of patients with intermediate stage HCC receive TACE, with the remainder deviating to a range of other therapies that have shown promise in select patient subgroups. These include curative treatments (resection, ablation, and liver transplantation), radiotherapy (stereotactic and radioembolization), systemic therapies, and their combination. In this review, we summarize the classifications and current management for patients with intermediate stage HCC as well as highlight recent key developments in this space.
出版者	SAGE PUBLICATIONS LTD
出版地	LONDON
ISSN	1758-8340
EISSN	1758-8359
卷号	12
DOI	10.1177/1758835920970840
页数	17
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:000590533600001
收录类别	SCIE ; SCOPUS ; PUBMED
URL	查看原文
PubMed ID	33224278
SCOPUSEID	2-s2.0-85095458945
通讯作者地址	[Lu, Xiao-Jie]Department of General Surgery,The First Affiliated Hospital of Nanjing Medical University,Nanjing,China ; [Ji, Jiansong]Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research,The Fifth Affiliated Hospital of Wenzhou Medical University/Affiliated Lishui Hospital of Zhejiang University,The Central Hospital of Zhejiang Lishui,Lishui,323000,China
Scopus学科分类	Oncology
引用统计	被引频次：15[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/19858
专题	其他_附属第五医院（丽水市中心医院）
通讯作者	Lu, Xiao-Jie; Ji, Jiansong
作者单位	1.AW Morrow Gastroenterology and Liver Centre,Royal Prince Alfred Hospital,Sydney,Australia; 2.Department of Hepatic Surgery,Fudan University Shanghai Cancer Center,Shanghai Medical College,Fudan University,Shanghai,China; 3.Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research,The Fifth Affiliated Hospital of Wenzhou Medical University/Affiliated Lishui Hospital of Zhejiang University,The Central Hospital of Zhejiang Lishui,Lishui,China; 4.Department of General Surgery,The First Affiliated Hospital of Nanjing Medical University,Nanjing,China; 5.Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research,The Fifth Affiliated Hospital of Wenzhou Medical University/Affiliated Lishui Hospital of Zhejiang University,The Central Hospital of Zhejiang Lishui,Lishui,323000,China
通讯作者单位	其他_附属第五医院（丽水市中心医院）
推荐引用方式 GB/T 7714	Prince, David,Liu, Ken,Xu, Weiqi,et al. Management of patients with intermediate stage hepatocellular carcinoma[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY,2020,12.
APA	Prince, David., Liu, Ken., Xu, Weiqi., Chen, Minjiang., Sun, Jin-Yu., ... & Ji, Jiansong. (2020). Management of patients with intermediate stage hepatocellular carcinoma. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12.
MLA	Prince, David,et al."Management of patients with intermediate stage hepatocellular carcinoma".THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 12(2020).